Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers
ZURICH, Switzerland, September 1, 2011 /PRNewswire/ –
Study Assessing the Safety and Efficacy of KUR-211 Expected to
Report in mid 2012
Kuros Biosurgery AG, a biotechnology company focused on the development
of novel biomaterials and bioactive-biomaterial combination products for
trauma, wound and spinal indications, announced today that it has completed
recruitment in a Phase IIb clinical trial designed to investigate KUR-211
(Viz.I-020201) in the treatment of diabetic foot ulcers.
This Phase IIb clinical trial is a randomised, multi-center, controlled,
parallel group dose-finding study to evaluate the efficacy and safety of
KUR-211 used as an adjunct to standard of care in patients with diabetic
foot ulcers. KUR-211 is a bioactive therapy intended for topical treatment
of diabetic foot ulcers, stimulating the granulation tissue formation, that
aids wound closure. The study evaluates the effects of KUR-211 applied twice
a week for maximum 16 weeks in addition to standard of care versus standard
of care (SOC) alone.
KUR-211 consists of a modified variant of platelet-derived growth factor
(PDGF) incorporated into a fibrin sealant and is applied to the wound as a
foam. The innovative Kuros “TG-hook” technology enables the PDGF to be
retained at the site for local exposure to migrating cells and for sustained
delivery of PDGF on enzymatic cleavage of the matrix. It is believed that
this novel approach may improve the frequency and speed of healing.
A total of 211 patients have been randomized and treated in over 27
centers across Europe including Russia. The primary endpoint of this study
is percentage reduction in ulcer surface area after 4 weeks of treatment
when compared to SOC alone. Patients are followed for 7 months following
initial treatment. Kuros is expecting to report the outcome of this study
around the middle of 2012.
Dr. Virginia Jamieson, Chief Medical Officer of Kuros, commented: “We
are very pleased to have completed recruitment for this study with KUR-211
and we look forward to reporting the results of this novel approach to the
treatment of diabetic foot ulcers.”
Kuros partnered with Baxter International Inc. for the development of
KUR-211 under a collaboration and license agreement that was signed in 2005.
Following the successful completion of this study, Kuros and Baxter will
look for a partner that takes over responsibility for the further
development of KUR-211.
About Diabetic Ulcers
There are approximately 285 million diabetics worldwide. Due to life
style issues and the aging population, this number is increasing. One in
three Americans born in 2000 is projected to develop diabetes.
Diabetic foot ulcers are a complication of diabetes that is caused by a
combination of a loss of sensitivity especially in the lower extremities and
vascular damage. The patients often do not sense damage to the skin, which
results in a small injury that develops into an ulcer. Due to impaired wound
healing capabilities and an increased risk for infection diabetic foot
ulcers often heal only very slowly or not at all, leading to major
implications for the affected patients.
Diabetic foot ulcers are a major medical, social and economic problem
worldwide with approximately 15 percent of diabetic patients developing an
ulcer in their lifetime and approximately 15 percent of those patients
developing an ulcer requiring an amputation.
Kuros is a biotechnology company that is focused on the development of
novel biomaterials and bioactive-biomaterial combinations for trauma, wound
and spinal indications.
Kuros’ combination products are designed to mimic the body’s natural
healing process. The products consist of fusion proteins of naturally
occurring bioactive factors, covalently incorporated into fibrin or
synthetic matrices. The incorporation of the biologically active molecules
into the injectable matrices aims to maximize their activity by retention at
the site of action. Kuros products are designed to combine ease of
application with localized delivery. Kuros has a number of methodologies to
achieve the desired retention and release profiles of the biologically
Kuros’ has a diverse pipeline of product candidates with its most
advanced products being in trauma and wound care.
Since its creation, Kuros has received over $150 million in funding. The
company is located in Zurich, Switzerland.
Press Enquiries Kuros Didier Cowling, CEO +41(0)44-200-56-62 Alistair Irvine, Director of Business Development +41(0)44-200-56-62 For International Media Enquires: Citigate Dewe Rogerson David Dible, Amber Bielecka, Nina Enegren +44(0)207-638-9571 For Swiss Media Enquires: sensus pr Jan Gregor +41(0)43-366-55-14
SOURCE Kuros Biosurgery AG